300 related articles for article (PubMed ID: 26215470)
1. Genomic approaches to identifying targets for treating β hemoglobinopathies.
Ngo DA; Steinberg MH
BMC Med Genomics; 2015 Jul; 8():44. PubMed ID: 26215470
[TBL] [Abstract][Full Text] [Related]
2. Fetal hemoglobin regulation in β-thalassemia: heterogeneity, modifiers and therapeutic approaches.
Sripichai O; Fucharoen S
Expert Rev Hematol; 2016 Dec; 9(12):1129-1137. PubMed ID: 27801605
[TBL] [Abstract][Full Text] [Related]
3. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
Steinberg MH
Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
[TBL] [Abstract][Full Text] [Related]
4. Pharmacological and molecular approaches for the treatment of β-hemoglobin disorders.
Lohani N; Bhargava N; Munshi A; Ramalingam S
J Cell Physiol; 2018 Jun; 233(6):4563-4577. PubMed ID: 29159826
[TBL] [Abstract][Full Text] [Related]
5. BCL11A is a major HbF quantitative trait locus in three different populations with beta-hemoglobinopathies.
Sedgewick AE; Timofeev N; Sebastiani P; So JCC; Ma ESK; Chan LC; Fucharoen G; Fucharoen S; Barbosa CG; Vardarajan BN; Farrer LA; Baldwin CT; Steinberg MH; Chui DHK
Blood Cells Mol Dis; 2008; 41(3):255-258. PubMed ID: 18691915
[TBL] [Abstract][Full Text] [Related]
6. Genome editing approaches to β-hemoglobinopathies.
Brusson M; Miccio A
Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
[TBL] [Abstract][Full Text] [Related]
7. Genetic Basis and Genetic Modifiers of β-Thalassemia and Sickle Cell Disease.
Thein SL
Adv Exp Med Biol; 2017; 1013():27-57. PubMed ID: 29127676
[TBL] [Abstract][Full Text] [Related]
8. Molecular basis of β thalassemia and potential therapeutic targets.
Thein SL
Blood Cells Mol Dis; 2018 May; 70():54-65. PubMed ID: 28651846
[TBL] [Abstract][Full Text] [Related]
9. Thiourea derivatives induce fetal hemoglobin production in-vitro: A new class of potential therapeutic agents for β-thalassemia.
Ali H; Iftikhar F; Shafi S; Siddiqui H; Khan IA; Choudhary MI; Musharraf SG
Eur J Pharmacol; 2019 Jul; 855():285-293. PubMed ID: 31100414
[TBL] [Abstract][Full Text] [Related]
10. Genetic association studies in β-hemoglobinopathies.
Thein SL
Hematology Am Soc Hematol Educ Program; 2013; 2013():354-61. PubMed ID: 24319204
[TBL] [Abstract][Full Text] [Related]
11. Future prospects for treatment of hemoglobinopathies.
Stamatoyannopoulos JA
West J Med; 1992 Dec; 157(6):631-6. PubMed ID: 1282285
[TBL] [Abstract][Full Text] [Related]
12. Hemoglobin switching's surprise: the versatile transcription factor BCL11A is a master repressor of fetal hemoglobin.
Bauer DE; Orkin SH
Curr Opin Genet Dev; 2015 Aug; 33():62-70. PubMed ID: 26375765
[TBL] [Abstract][Full Text] [Related]
13. Discovering the genetics underlying foetal haemoglobin production in adults.
Thein SL; Menzel S
Br J Haematol; 2009 May; 145(4):455-67. PubMed ID: 19344402
[TBL] [Abstract][Full Text] [Related]
14. Molecular genetics of β-thalassemia: A narrative review.
Jaing TH; Chang TY; Chen SH; Lin CW; Wen YC; Chiu CC
Medicine (Baltimore); 2021 Nov; 100(45):e27522. PubMed ID: 34766559
[TBL] [Abstract][Full Text] [Related]
15. Integrative microRNA and gene expression analysis identifies new drug repurposing candidates for fetal hemoglobin induction in β-hemoglobinopathies.
Das SS; Sinha R; Chakravorty N
Gene; 2019 Jul; 706():77-83. PubMed ID: 31048070
[TBL] [Abstract][Full Text] [Related]
16. Genotypic heterogeneity and correlation to intergenic haplotype within high HbF beta-thalassemia intermedia.
Papachatzopoulou A; Kourakli A; Makropoulou P; Kakagianne T; Sgourou A; Papadakis M; Athanassiadou A
Eur J Haematol; 2006 Apr; 76(4):322-30. PubMed ID: 16519704
[TBL] [Abstract][Full Text] [Related]
17. Genomic variants in members of the Krüppel-like factor gene family are associated with disease severity and hydroxyurea treatment efficacy in β-hemoglobinopathies patients.
Stratopoulos A; Kolliopoulou A; Karamperis K; John A; Kydonopoulou K; Esftathiou G; Sgourou A; Kourakli A; Vlachaki E; Chalkia P; Theodoridou S; Papadakis MN; Gerou S; Symeonidis A; Katsila T; Ali BR; Papachatzopoulou A; Patrinos GP
Pharmacogenomics; 2019 Jul; 20(11):791-801. PubMed ID: 31393228
[No Abstract] [Full Text] [Related]
18. Lentiviral and genome-editing strategies for the treatment of β-hemoglobinopathies.
Magrin E; Miccio A; Cavazzana M
Blood; 2019 Oct; 134(15):1203-1213. PubMed ID: 31467062
[TBL] [Abstract][Full Text] [Related]
19. [Progress on genes related to fetal hemoglobin quantitative trait].
Guo XQ
Yi Chuan; 2010 Apr; 32(4):295-300. PubMed ID: 20423883
[TBL] [Abstract][Full Text] [Related]
20. Targeted therapeutic strategies for fetal hemoglobin induction.
Sankaran VG
Hematology Am Soc Hematol Educ Program; 2011; 2011():459-65. PubMed ID: 22160074
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
